Adeel Rabbani
Child & Adolescent Psychiatry · Vestavia Hls, ALNPI 1083751374
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 28.3% of the total. Reporting peaked in 2019 at $446 and has fallen 58.6% since, to $185 in 2025.
Across 62 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$314
- Otsuka America Pharmaceutical, Inc.$137
- Lemaitre Vascular, Inc.$121
- Sunovion Pharmaceuticals Inc.$87
- Neos Therapeutics, LP$76
- Bausch Health US, LLC$75
- plus $299 from 11 others
What the payments were for
- Food & beverage$1,109100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $314 |
| Otsuka America Pharmaceutical, Inc. | 10 | $137 |
| Lemaitre Vascular, Inc. | 1 | $121 |
| Sunovion Pharmaceuticals Inc. | 8 | $87 |
| Neos Therapeutics, LP | 5 | $76 |
| Bausch Health US, LLC | 5 | $75 |
| Neuronetics, Inc. | 4 | $63 |
| Johnson & Johnson | 2 | $37 |
| Adlon Therapeutics L.p. | 2 | $32 |
| AbbVie(2 entities) | 2 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 2 | $27 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Tris Pharma Inc | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,109 in reported general payments places this provider in the 60th percentile of 40 child & adolescent psychiatry providers in Alabama.
See all child & adolescent psychiatry providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 11 | $5,110 |
| Vilazodone Hcl | 16 | $2,714 |
| Aripiprazole | 56 | $2,529 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 23 | $2,111 |
| Duloxetine Hcl | 68 | $1,385 |
| Quetiapine Fumarate | 72 | $1,114 |
| Bupropion XlBupropion Hcl | 35 | $954 |
| Lurasidone Hcl | 15 | $946 |
| Ziprasidone Hcl | 12 | $794 |
| Olanzapine | 22 | $662 |
| Buspirone Hcl | 38 | $568 |
| Lamotrigine | 22 | $563 |
| Hydroxyzine Hcl | 28 | $460 |
| Mirtazapine | 17 | $444 |
| Sertraline Hcl | 37 | $434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $314 | $5,11011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 40 child & adolescent psychiatry providers in Alabama.
Other child & adolescent psychiatry in Vestavia Hls
- Nelson HandalDothan$80K
- Artie NelsonBirmingham$32K
- Jerlyn McCleodDothan$9K
- Karen CallahanBirmingham$5K
- Curtis AdamsHuntsville$5K
- Casey LowreyBirmingham$4K
- Aparna VuppalaHuntsville$3K
- Richard SinclairMobile$2K
- John Broderick-CantwellDaphne$2K
- Christiana WilkinsOpelika$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.